Large-cell Neuroendocrine Carcinoma of the Endometrium in Myomatous Uterus

Shopov, Spasimir Todorov; Anavi, Benyamin L; Krastev, Dobrin K

doi:10.3897/folmed.62.e49815

Cited by 2 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This multicenter study suggested that stage III-IV disease and pure SCNEC are associated with significantly poorer prognosis than other disease stages and histological types. However, some studies have reported long-term survival in patients with advanced disease (10,12,16) SCNEC treated with surgery + CT (cisplatin + etoposide) + RT, and their patient remained alive 5 years later. The current study included the largest cohort of patients with NETs of the endometrium to date.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Primary Neuroendocrine Tumors of the Endometrium: Management and Outcomes

Zhang

Pang

2022

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveTo analyze clinical behavior of, optimal treatment regimens for, outcomes, and prognosis of 170 patients with neuroendocrine tumors (NETs) of the endometrium.MethodsThe Surveillance, Epidemiology, and End Results database was used to identify patients with endometrial NETs diagnosed between 2004 and 2015. Clinical features and treatment regimens were analyzed, and 5-year overall survival (OS) and cancer-specific survival (CSS) were compared among different stages and treatment regimens. Univariate and multivariate analyses were performed to identify independent prognostic factors associated with endometrial NETs. Finally, prognosis was compared between small- and large-cell neuroendocrine carcinoma (SCNEC and LCNEC, respectively) of the endometrium.ResultsThere were 20, 8, 47, and 95 patients with stage I, II, III, and IV NET, respectively. The 5-year OS rates of patients in each stage were 59.86%, 42.86%, 32.75%, and 6.04%, respectively. The 5-year CSS survival rates were 59.86%, 50.0%, 38.33%, and 6.39%, respectively. In the multivariate analysis, American Joint Committee on Cancer (AJCC) stage and treatment were associated with poor OS, while AJCC stage, nodal metastasis, and treatment were associated with poor CSS. Neither pathological type nor distant metastasis was associated with prognosis. The rate of distant metastasis was significantly higher for LCNEC than for SCNEC, while 5-year OS and CSS rates were significantly lower.ConclusionComplete surgical treatment should be selected regardless of staging for patients with endometrial NETs. For early-stage disease, individualized postoperative treatment with single chemotherapy or radiotherapy may improve OS and CSS. For advanced-stage disease, comprehensive postoperative adjuvant therapy may improve OS and CSS.

show abstract

Section: Discussionmentioning

confidence: 99%

“…This multicenter study suggested that stage III–IV disease and pure SCNEC are associated with significantly poorer prognosis than other disease stages and histological types. However, some studies have reported long-term survival in patients with advanced disease ( 10 , 12 , 16 ). Sawada et al.…”

Section: Discussionmentioning

confidence: 99%

Primary Neuroendocrine Tumors of the Endometrium: Management and Outcomes

Zhang

Pang

2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…10,12,13 These treatments were based on some data of small cell lung cancer, but there was no large-scale study or prospective clinical trial to guide the treatment of ENC. The commonly used chemotherapy regimens of NECA include etoposide and platinum drugs, 14,15 such as etoposide/cisplatin, carboplatin/paclitaxel. 12 Studies have shown that immediate surgery and chemotherapy were preferable to prolong disease-free survival and maintain a good performance status.…”

Section: Discussionmentioning

confidence: 99%

Clinical characteristic and prognostic factors in high‐grade endometrial neuroendocrine carcinoma

Zhang

Wang

et al. 2022

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Aim:The aim of the present study was to summarize the clinical characteristics and analyze the independent prognostic factors in patients with high-grade endometrial neuroendocrine carcinoma (ENC). Methods: Patients diagnosed with ENC, endometrioid adenocarcinoma (EAC), endometrial clear-cell carcinoma (ECC), endometrial serous carcinoma (ESC), endometrioid carcinoma with mucinous features (EMC) from 1987 to 2016 were screened from the National Cancer Institute database (surveillance, epidemiology, and end results [SEER]). Kaplan-Meier were used to assess survival. Univariate and multivariate Cox proportional hazards analysis were done to examine factors affecting survival. Results: The median survival times of ENC were 11 months, shorter than that of EAC, ECC, ESC, and EMC (p < 0.01). There was no significant difference in ages, survival rate, and median survival time between largecell ENC (LCENC) and small-cell ENC (SCENC), which were all belong to ENC. In a multivariable model, the hazard ratio (HR) of death for women with Federation International of Gynecology and Obstetrics (FIGO) stage I-II of ENC was 0.37 compared to FIGO stage III-IV (p < 0.01). The HR of patients who under the surgery was 0.39 compared to the patients who without surgery (p < 0.01), and the HR of patients who received chemotherapy was 0.51 compared to the patients who did not received chemotherapy (p < 0.01). Radiotherapy did not significantly reduce the mortality risk of patients. Conclusion: ENC was a kind of devastating endometrial cancers with the poorest prognosis. Surgical treatment and chemotherapy were necessary for improving prognosis of ENC. Early diagnosis favored better prognosis. There was no prognostic difference between with and without radiotherapy.

show abstract

Large-cell Neuroendocrine Carcinoma of the Endometrium in Myomatous Uterus

Cited by 2 publications

References 10 publications

Primary Neuroendocrine Tumors of the Endometrium: Management and Outcomes

Primary Neuroendocrine Tumors of the Endometrium: Management and Outcomes

Clinical characteristic and prognostic factors in high‐grade endometrial neuroendocrine carcinoma

Contact Info

Product

Resources

About